Synthesis, characterization, and cytocompatibility of potential cockle shell aragonite nanocrystals for osteoporosis therapy and hormonal delivery

Alhaji Zubair Jaji1,2
Md Zuki Bin Abu Bakar1,3
Rozi Mahmud4
Mohamad Yusof Loqman5
Mohamad Noor Mohamad Hezmee1
Tijani Isa3
Fu Wenliang3
Nahidah Ibrahim Hammadi1
1Department of Veterinary Pre-Clinical Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; 2Department of Veterinary Anatomy, Faculty of Veterinary Medicine, University of Ilorin, Ilorin, Kwarra, Nigeria; 3Molecular Biomedicine Laboratory, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; 4Department of Imaging, Faculty of Medicine and Health Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; 5Department of Companion Animal Medicine and Surgery, Universiti Putra Malaysia, Serdang, Selangor, Malaysia

Abstract: Calcium carbonate is a porous inorganic nanomaterial with huge potential in biomedical applications and controlled drug delivery. This study aimed at evaluating the physicochemical properties and in vitro efficacy and safety of cockle shell aragonite calcium carbonate nanocrystals (ANC) as a potential therapeutic and hormonal delivery vehicle for osteoporosis management. Free and human recombinant parathyroid hormone 1-34 (PTH 1-34)-loaded cockle shell aragonite calcium carbonate nanocrystals (PTH-ANC) were synthesized and evaluated using standard procedures. Transmission electron microscopy and field emission scanning electron microscopy results demonstrated highly homogenized spherical-shaped aragonite nanocrystals of 30±5 nm diameter. PTH-ANC had a zeta potential of −27.6 ± 8.9 mV. The encapsulation efficiency of the formulation was found to be directly proportional to the concentrations of the drug fed. The X-ray diffraction patterns revealed strong crystalizations with no positional change of peaks before and after PTH-ANC synthesis. Fourier transform infrared spectroscopy demonstrated no detectable interactions between micron-sized aragonite and surfactant at molecular level. PTH-ANC formulation was stabilized at pH 7.5, enabling sustained slow release of PTH 1-34 for 168 h (1 week). A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cytocompatibility assay in Human Foetal Osteoblast Cell Line hFOB 1.19 showed that ANC can safely support osteoblast proliferation up to 72 h and beyond due to the sustained slow release of PTH 1-34. It was concluded that due to its biogenic nature, ANC is a cytocompatible antosteoporotic agent. It doubles as a nanocarrier for the enhancement of efficacy and safety of the bone anabolic PTH 1-34. ANC is expected to reduce the cost, dosage, and dose frequency associated with the use of PTH 1-34 management of primary and secondary forms of osteoporosis.

Keywords: bone, FESEM, FT-IR, MTT viability, PTH 1-34, sustained release, TEM, XRD, zeta potential

Introduction

Bone undergoes continuous adjustments (remodeling) by resorption of old bones by osteoclast and formation of new bones by osteoblast.1 These activities are normally stable and under physical and hormonal control. Imbalances between osteoclast and osteoblast activities characterized by bone resorption at a level that exceeds the rate of bone formation have been found to be responsible for osteoporosis and its associated bone loss and skeletal fragility.2 Osteoporosis and its associated fractures have been predicted as a disease with potentials of increased public health importance in future generations, possibly due to increase in life expectancy.3
The recombinant human parathyroid hormone 1-34 (PTH 1-34) is commercially known as Teriparatide. Forteo is a 4117.8 Da peptide approved by the Food and Drug Administration as a therapeutic agent for osteoporosis.4 PTH 1-34 is a potent bone anabolic that treats osteoporosis by prompting remodeling cascades in osteogenic cells through the stimulation of bone matrix production and suppression of osteoblast apoptosis.5,6 PTH 1-34 has a high absolute bioavailability, rapid absorption, and disposition after a single subcutaneous administration in healthy rats. It displayed a characteristic mono-exponential swift and substantial absorption and decline, with respective absolute bioavailability and elimination half-life of 65% and 3.4–4.1 h. Approximately 6% of the administered PTH 1-34 was excreted into bile for up to 24 h after administration, whereas ~91% were recovered in urine and 2% were recovered from feces after 72 h of administration. Based on available data from 10, 20, and 40 µg subcutaneous doses of PTH 1-34 in humans, it is concluded that the absolute bioavailability of PTH 1-34 is ~95%. PTH 1-34 has a rapid rate of absorption and elimination. It reaches peak serum concentrations in 30 min after subcutaneous administration of a 20 µg dose and drops to an undetectable concentration within 3 h. It has a distribution of ~0.12 L/kg after intravenous injection and a half-life in serum of ~5 min when injected intravenously and ~1 h when administered by subcutaneous injection. Due to its short life and fast clearance, PTH 1-34 peptide is presently injected subcutaneously daily for 2 years. Thus, there is a pressing need to improve patient compliance through the reduction of frequency of injection or sorting for a feasible alternate route of administration that will prolong the time taken for the peptide to be exposed to serum. A PTH 1-34-loaded nanoformulation can enable sustained slow release of its anabolic dose and rule out possible side effects associated with its sudden exposure into patient’s blood. Moreover, studies have shown that blood clearance of the smaller nanoparticles was twice as slow as those of larger nanoparticle formulations.

Calcium is the fifth most abundant element in the body. It is an important structural component of bone and teeth and is also necessary for the normal functioning of all the muscles (skeletal, heart, and smooth muscles) and nerves as well as the normal clotting of blood. Prolonged, inadequate intake of calcium causes weak bones (osteoporosis). Products containing calcium carbonate (CaCO₃) are used to increase the intake of calcium in individuals whose diets are low in calcium. The National Institutes of Health recommend 1000–1500 mg of calcium per day as part of regimen to prevent the loss of bone associated with aging. CaCO₃ products contain 40% absorbable calcium. Therefore, a 1500 mg tablet of CaCO₃ provides 600 mg of calcium. CaCO₃ is also used as an antacid for treating stomach distress.51 CaCO₃ is a calcium salt found in limestone, chalk, marble, plant ashes, bones, many shelled mollusks, and coccolithophores. It is also obtained as a white precipitate by passing carbon dioxide into a suspension of calcium hydroxide in water. It is used in dentifrices and in pharmaceuticals as an antacid and to supplement bodily calcium stores.12,13 It has presently become popular in the field of nanotechnology as a highly biocompatible porous compound. It has an easily manipulative physicochemical properties, surface chemistry (shape and size), and method of production at a large scale.14 It is pH sensitive, and its solubility is exponentially and inversely proportional to its pH.15 These make it a novel inorganic material with a huge potential in biomedical applications and controlled drug delivery.16

The cockle shell (Anadara granosa)-derived aragonite CaCO₃ nanocrystals (ANC) is the chosen nanocarrier for this study. ANC is an inorganic nanocrystal synthesized using the top-down approach of nanoparticle preparation. Cockles are dominant faunal bivalves present, sometimes comprising the entire bivalve fauna in deep shell beds on sandy mud flats in the upper parts of estuaries and harbors. They live in super abundance in the low tidal and shallow subtidal zones of most of our present-day estuaries and enclosed bays and harbors.17 In Malaysia, the cockle shells (A. granosa) are cultivated in a large scale in the area of intertidal coastal bordering mudfield regions and in many parts of South East Asian countries, mainly Thailand and Indonesia. They are by far the most vital species cultured in Malaysia.18 The cockle shells contain >98% of CaCO₃ and thus has the potential for the development of biomaterials for orthopedic applications.19

Aragonite CaCO₃ polymorph is a thermodynamically less stable and less available form of crystalline CaCO₃ synthesized in laboratory. The size and shape of aragonite are strongly dependent on the preparation methods and conditions.20 Due to the huge striking properties of aragonite nanoparticles as a material of biomedical importance, researchers have paid huge attention in the invention of methods for controlled and facile synthesis of aragonite nanoparticles of appropriate sizes and shapes using bottom-up methods.21,22 Yet, none of these methods can promise the production of pure aragonite nanoparticles of suitable sizes and shapes. Aragonite resulting from these methods of production is often mixed with calcite21 or calcite and vaterite.23 Therefore, these methods may not be appropriate for specific biomedical applications. Though carbonation methods are found to be useful in industries
and environmentally friendly, they are associated with the need for strict control of temperature, purified raw materials, and strenuous gas (CO₂ or combination of CO₂ and N₂) bubbling phases which are complicated, expensive, and time-consuming. Other impurities such as BS-12 are also added to the final products. Therefore, the top-down approach of ANC synthesis from its natural sources, for example, cockle shells or sea shells is greatly promising.

This study is in line with the global efforts at tackling the menace of osteoporosis and its associated complications. It aimed at synthesis, physicochemical characterizations, and in vitro evaluation of the ANC as a potential therapeutic and nanocarrier for sustained slow release of anabolic antiosteoporotic PTH 1-34. The PTH 1-34-loaded cockle shell aragonite calcium carbonate nanocrystals (PTH-ANC) will result in reducing dosage, cost, side effect, and dosing frequency of PTH 1-34, toward an effective management of primary and secondary forms of osteoporosis and better compliance from patients.

**Materials and methods**

**Preparation of PTH 1-34-loaded cockle shell aragonite calcium carbonate nanocrystals (PTH-ANC)**

**Preparation of micron-sized aragonite CaCO₃ (MAC) powder**

MAC preparation entailed scrubbing of dirt and tissues from ~250 g of the cockle shells. The cleaned shells were boiled for 10 min and then cooled to room temperature. The shells were thoroughly washed with distilled water and then oven-dried in Memmert UM500 oven (GmbH Co, Schwabach, Germany) at 50°C for 7 days. The shells were then powdered with mortar and pestle (Agate Top diameter 90 mm), finely ground with a stainless steel blender (Blendor®, HCB 550, Stamford, CT, USA), and sieved using a 75 µm aperture-sized stainless steel laboratory test sieve (Endecott Ltd., London, UK) to get 75 µm diameter-sized particles. The coarse unfiltered remnants were further dried in oven for 10 h, ground with mortar and pestle, blended and sieved to further reduce their diameter. The micron-sized cockle shell powder thus produced was further desiccated in an oven at 50°C for a 7 days duration for complete dry up. The MAC was then packaged in a JP Packaging polyethylene plastic bag.

**Preparation of spherical-shaped aragonite CaCO₃ nanocrystals (ANC)**

Approximately 2 g of the 75-µm-sized powder was placed in a 100-mL flat-bottomed flask, mixed with 50 mL of high performance liquid chromatography (HPLC)-grade (resistance >18 M cm), produced by a Milli-Q Water System (Organex, São Paulo, Brazil). Approximately 0.5 mL of dodecyl dimethyl betaine (BS-12) (Sigma Aldrich, St Louis, MO, USA) was then added to each flask and stirred vigorously at 1000 rpm in room temperature for 90 min using a Systematic Multi-Hotplate stirrer (DH.WMH03506 DAIHAN WiseStir® Systematic Multi-Hotplate Stirrers, 3 x 2 Places, 6 Positions, South Korea) and a magnetic stirrer bar. The slurry obtained from this process was filtered and rinsed with 18.0-cm-sized double ring filter papers (Filtres Fioroni, Ingréd, France). The final products were dried in Memmert UM500 oven (GmbH Co) for 24 h at 100°C and packed in JP Packaging polyethylene plastic bags and stored in moisture-free enclosure (at 50°C) for further analysis and usage.

**Synthesis of PTH-ANC**

PTH-ANC was synthesized by separately adding different concentrations (1 x 10⁻³, 2 x 10⁻³, and 4 x 10⁻³ mg/mL) of aqueous solutions of PTH 1-34 into 10 mL cockle shell aragonite CaCO₃ nanocrystal (ANC) suspensions of 0.1% (w/v) concentration. This research was aimed at studying the drug content and encapsulation efficiency of ANC. The encapsulations of PTH 1-34 in CaCO₃ nanocrystals were achieved by incubating the resulting solutions overnight at 4°C under constant stirring. The PTH-ANC suspensions obtained were centrifuged at 10,000 x g for 10 min, and the pelleted nanocrystals were steadily dried at 4°C.

**Drug content and encapsulation efficiency of ANC**

The amount of PTH 1-34 in solution was measured using Human PTH 1-34 Enzyme Immunoassay kit (EK-055-08, Phoenix Pharmaceuticals Company Inc., Karlsruhe, Germany) protocols. The immunoplate in this kit was precoated with secondary antibody with blocked nonspecific binding sites. A standard curve of known concentration was established (Figure S1) and unknown concentrations in samples were calculated using the equation of the curve. The drug content and drug encapsulation efficiency were calculated using Equations 1 and 2 as adopted from Rajat et al.

\[
\text{Drug content} (%) = \frac{\text{tdf} - \text{fd}}{\text{wnr}} \times 100 \quad (1) 
\]

\[
\text{Drug encapsulation efficiency} (%) = \frac{\text{tdf} - \text{fd}}{\text{tdf}} \times 100 \quad (2) 
\]

where tdf refers to the total drug fed to the formulation, fd refers to the free drug, and wnr refers to the weight of nanocrystals recovered from the formulation.
Physicochemical characterization of ANC and PTH-ANC

Transmission electron microscopy (TEM)
The TEM (Hitachi H-7100; Hitachi Ltd., Tokyo, Japan) was used to determine the shape and size of ANC. Sample preparation for TEM entailed dispersal of a pinch of ANC powder in 100% acetone, followed by ultra-sonication (Power Sonic 505; Gangnam-gu, South Korea) for 30 min. A drop of the supernatant was then placed onto a carbon-cover copper grids placed on a filter paper and left to dry at room temperature. The TEM measurement was made at 150 kV.

Field emission scanning electron microscopy (FESEM)
The FESEM (JEOL 7600F; JEOL, München, Germany) GmbH was used to evaluate homogeneity and further evaluate the shape and size of ANC. Sample preparation for FESEM entailed dispersal of a light pinch of ANC powder on adhesive-coated metallic stub. The so-prepared stub was then installed into the FESEM microscope and the microscopy measured.

Zeta potential
Pelleted PTH-ANC was resuspended in deionized water. The mean zeta potential of the PTH-ANC was based on dynamic light scattering determined by photon correlation spectroscopy using Zetasizer (Ver. 6.12, Serial Number: MAL1042820; Malvern Instruments Ltd., Malvern, UK).

Fourier transform infrared (FT-IR) spectrophotometry
The FT-IR spectrophotometer (Model 100 series; Perkin Elmer) was used to analyze the chemical properties of PTH I-34, PTH-ANC, ANC, and MAC over a range of 4000 to 280 cm⁻¹ at a 2 cm⁻¹ resolution and averaging 64 scans.

X-ray powder diffraction (XRD)
In this study, the composition, purity, and crystallinity of PTH I-34, PTH-ANC, ANC, and MAC were studied by an X-ray powder diffractometer (Shimadzu XRD-6000 powder diffractometer with CuKα [λ=1.540562 Å] at 40 kV and 30 mA). A standard back fill method was used in preparation of samples for XRD. This entailed packing ~0.35 g of powder into the holder for a 90° tilt test. The holder was sufficiently firm enough to prevent the sample from falling out during the test. The crystallinity phases were determined with diffraction angles from 20° to 70° at 37°C.

Drug release profile of PTH-ANC
The release profile of PTH-ANC was determined at pH 7.5 within a span of 168 h. This entailed centrifuging of PTH-ANC suspension at 20,000 rpm for 45 min and the pellet thereby obtained was dispersed in 10 mL of phosphate-buffered saline solution of pH 7.5 with a final concentration of 2.5 × 10⁻³ mg/mL. Entire volume obtained was divided equally into the required number of Eppendorf tubes for the time-specific release study at time intervals 0, 0.5, 1, 3, 6, 9, 12, 24, 48, 72, 96, 120, 144, and 168 h. Tubes were incubated at 37°C under gentle shaking in the YIH DER orbital shaker incubator TU-400. At appropriate time intervals, the contents of the Eppendorf tubes were centrifuged, and PTH 1-34 released from PTH-ANC was later quantified using Human PTH 1-34 Enzyme Immunoassay (EK-055-08; Phoenix Pharmaceuticals Company Inc., Karlsruhe, Germany). The percentage of PTH 1-34 peptide released was calculated based on the ratio of the amount of peptide released at a given time to the amount loaded in the formulation, as below:

\[
\text{% of PTH 1-34 released} = \frac{\text{Quantity of PTH 1-34 released at time } "t"}{\text{Quantity of PTH 1-34 loaded in the formulation}} \times 100 \quad (3)
\]

The percentage of PTH 1-34 peptide released was plotted against each time period to obtain a cumulative graph depicting the release profile.

Cell culture
The hFOB 1.19 (ATCC® CRL11372™) cell line was cultured in 5% CO₂ in air atmosphere incubator, Sanyo inCu safe incubator (Sanyo MCO-18AIC (UV); Osaka, Japan), at 34°C using a T75 culture flask in Ham's F12 Medium Dulbecco’s Modified Eagle's Medium, with 2.5 mM L-glutamine (without phenol red) and 100 µg/mL each of penicillin and streptomycin.

The total viable cell population and seeding rate were calculated as below:

Average live cells = \frac{\text{sum of live cells counted from chambers}}{\text{number of chambers counted}}

\[
= \frac{38 + 36 + 40 + 42}{4} = \frac{156}{4} = 39
\]

Average dead cells = \frac{\text{sum of dead cells counted from chambers}}{\text{number of chambers counted}}

\[
= \frac{5 + 4 + 4 + 3}{4} = \frac{16}{4} = 4
\]
Viability (%) = \( \frac{\text{number of live cells}}{\text{number of live + dead cells}} \times 100 \)

\[
\frac{39}{43} \times 100 = 91\%
\]

Cell density (cells/mL) = \( \frac{\text{average live cells} \times \text{dilution factor}}{\text{volume of a square (mL)}} \)

\[
= \frac{39 \times 2}{0.0001 \text{ mL}} = 780,000 \text{ cell/mL}
\]

Total cells = cell density \( \times \) volume of cell suspension

\[
= 580,000 \times 4 = 3,900,000 \text{ cells} = 3.9 \times 10^6 \text{ cells}
\]

**MTT relative proliferation assay**

A 72-h MTT viability of hFOB 1.19 (ATCC® CRL11372™) due to effects of PTH 1-34, ANC, and PTH-ANC was assayed using the calculated total viable cell population and the final required volume. Approximately 100 µL cell suspensions, each containing 10,000 cells were seeded per well in the 96-well Greiner flat-bottomed well plates. Cells were then incubated for 24–72 h.

During each experiment, the media were removed and the cells were cultured with 100 µL of different concentrations of PTH 1-34, ANC, and PTH-ANC (20, 10, 5, 2.5, and 0 µg/mL). The experiment was conducted in triplicates, and the optical densities were measured at 570 nm.

**Results**

**Drug content and encapsulation efficiency of ANC**

Table 1 shows the PTH 1-34 content and encapsulation efficiency of ANC from three formulations. It was observed that the drug content and encapsulation efficiency were directly proportional to the amount of drug fed into the formulation.

**Table 1** Drug loading concentrations, drug contents, and encapsulation efficiencies of PTH-ANC

<table>
<thead>
<tr>
<th>Samples</th>
<th>Weight of ANC (mg)</th>
<th>Weight of PTH 1-34 (mg)</th>
<th>PTH 1-34 content (%)</th>
<th>Encapsulation efficiency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTH-ANC (1)</td>
<td>10</td>
<td>0.04</td>
<td>0.39</td>
<td>97.83</td>
</tr>
<tr>
<td>PTH-ANC (2)</td>
<td>10</td>
<td>0.02</td>
<td>0.19</td>
<td>94.45</td>
</tr>
<tr>
<td>PTH-ANC (3)</td>
<td>10</td>
<td>0.01</td>
<td>0.09</td>
<td>85.2</td>
</tr>
</tbody>
</table>

**Abbreviations:** ANC, aragonite calcium carbonate nanocrystals; PTH 1-34, parathyroid hormone 1-34; PTH-ANC, PTH 1-34-loaded cockle shell aragonite calcium carbonate nanocrystals.

**Physicochemical characterization of ANC and PTH-ANC**

**TEM**

Figure 1 shows the shape and size of ANC as viewed under transmission electron microscope. The micrograph images at lower magnification revealed the spherical-shaped nanocrystals of 30 ± 5 nm in size.

**FESEM**

Figure 2 shows the shape and size of ANC as viewed under field emission scanning electron microscope. The spherical particles were fairly uniform in size and 30 ± 5 nm in diameter.
Zeta potential
Figure 3 shows the zeta potential distribution of PTH-ANC. The product was found to have a zeta potential of $-27.6 \pm 8.9$ mV.

FT-IR spectra
Figure 4 compares the FT-IR spectra of PTH 1-34, PTH-ANC, ANC, and MAC. The spectra were composed of bands ranged from 4000 to 280 cm$^{-1}$. Most of the peaks of the four products matched with one another, meaning that the purity of the MAC is not affected by the top-down method of ANC synthesis using BS-12 and that PTH 1-34 is well conjugated with ANC, forming PTH-ANC. The carbonate absorption peaks (1449, 1083, 857, and 714 cm$^{-1}$) were clearly obvious in the MAC, ANC, and PTH-ANC spectra patterns.

XRD
Figure 5 shows that the XRD absorption peaks in the PTH-ANC, ANC, and MAC matched with one another. This means that the crystalline quality of aragonite CaCO$_3$ in these powders is maintained throughout the process of PTH-ANC production.

Drug release profile of PTH-ANC
Figure 6 and Table S1 depict PTH 1-34 release profile from PTH-ANC. They depict the cumulative PTH 1-34 released from 2.5 mg PTH-ANC (containing 9.8 µg PTH 1-34) over a week (168 h) period at pH 7.5, as quantified with the Human PTH 1-34 Enzyme Immunoassay (EK-055-08; Phoenix Phar-
maceuticals Company Inc., Karlsruhe, Germany). The release profile was characterized by an initial burst release at 0 h followed by a marked decline at 0.5 h and steady rise to attain a highest peak by 24 h. It was then sustained for the remaining period of the release.

MTT relative proliferation assays

Figure 7 depicts the 72 h MTT proliferation assays of PTH 1-34, ANC, and PTH-ANC at 20, 10, 5, 2.5, and 0 µg/mL on the hFOB 1.19 (ATCC® CRL11372™) cell line. It was observed that relative to the control, all the three treatments supported the proliferation of the osteoblast cells at the said period in a concentration-dependent manner. Generally, ANC and PTH-ANC gave better performance in the 24- and 48-h periods. ANC had the best performance in the 24 and 48 h, whereas PTH-ANC performed best at the 72-h period due to the sustained release of its encapsulated PTH 1-34.

Discussion

Physicochemical characterization and in vitro bioassays have been identified as essential parts of an ideal characterization plan of nanoparticles prior to biomedical applications. This is to fully understand their efficacy and safety, the other component being in vivo studies.27 Cockle shells are excellent sources of naturally purified aragonite polymorph of CaCO3.25 Although CaCO3 is renowned for its multifaceted applicability in the fields of human endeavours,9,20,25,28–31 it is poised for greater advancement through nanotechnology. Nanotechnology offers numerous prospects and gains to medical research by making pharmaceuticals more effective.27 The nanotechnological top-down synthesis of CaCO3 nanoparticles, by reducing the volume of surfactant and quantity and size of MAC used per round of synthesis from 2 mL, 5 g, and 90 µm to 0.5 mL, 2 g, and 75 µm, respectively, while maintaining other parameters therein (stirring speed, time, and temperature). This enhanced the homogeneity and overall quality and
safety of the synthesized crystals for biological applications, while improving its environmental friendliness and low-cost features. Although surfactant inclusions in nanoformulations promote the dispersion of nanoparticles, they also interfere with conventional characterization methods and cause ambiguity in analytical results. They thus hamper the standardization of characterization techniques and clinical application of nanoparticles. The modified technique thus enabled the synthesis of highly homogenized spherical shape ANC of 30 ± 5 nm size, as determined by TEM and FESEM. This size concurs with the size of CaCO₃ synthesized by Islam et al. and smaller than that of Kamba et al. using the homogenizer method. The size fell within the range of sizes ideal for drug delivery. The –27.6 ± 8.9 mV zeta potential obtained from this present study is an improvement over those earlier workers, due to its incorporated PTH 1–34. Although morphology, structure, surface area, size, oil adsorption, and chemical purity are important determinant factors for the use of CaCO₃ in varying applications, morphology seems to be more important. As such, synthesis of CaCO₃ crystals with homogenous shape and size is now a topic of research due to the interesting mechanical and optical properties. The loading content of PTH 1–34 and the encapsulation efficiency of ANC in the PTH-ANC composition were directly proportional to the concentrations of the drug fed. The formulations used have a loading content of 0.09%, 0.19%, and 0.39% and encapsulation efficiency of 85.2%, 94.45%, and 97.83% after 10 mg of ANC was separately loaded with 0.01, 0.02, and 0.03 mg of PTH 1–34. Calcium carbonate nanocrystals have been observed to contain surface pores (nanopores) that enable them load drugs or macromolecules by capillary force, irrespective of their surface charge and hydrophilicity.

The FTIR spectra of PTH 1–34, MAC, ANC, and PTH-ANC were composed of bands ranging from 4000 to 280 cm⁻¹. FTIR spectroscopy is a precise technique for identifying diverse phases of organic and inorganic compounds. It is a useful instrument for characterizing CaCO₃ phases based on dissimilarities in their constituent carbonate ions. Carbonate ions and alike molecules, normally have four (v₁ to v₄) vibrational peak modes: symmetric stretching, out-of-plane bending, doubly degenerate planar asymmetric stretching, and doubly degenerate planar bending. The observed absorption peaks in this study (1449, 1083, 857, and 714 cm⁻¹) fell within the ranges that were earlier described as characteristic peaks for carbonates in CaCO₃ and correspond to the v₁ to v₄ vibrations with some structural changes. These changes are attributed to the shift of the carbonate vibration mode in the milieu of oxygen atoms and the associated modification of the electrostatic valence of the Ca–O bond. Similar peaks were reported by Raju et al. and Islam et al. using the aragonite phase of CaCO₃ spectrum, whose carbonate ions are indiscernible in the infrared region. The absorption peaks in MAC correspond to those of ANC. The PTH 1–34 loading in ANC was established by sharp peaks at 1670, 1449, 1083, 857, and 714 cm⁻¹ of ANC in accommodating the amine component of the PTH 1–34 absorption peaks in the formation of PTH-ANC. In the same vein, a sharp peak was observed at 2520 cm⁻¹ of ANC in accommodating the carboxyl component of the PTH 1–34 absorption peaks.

XRD is a sensitive test that is used for the recognition of crystalline phases of inorganic compounds. XRD absorption peaks in PTH-ANC, ANC, and MAC matched with one another without positional shift. Two prominent peaks were found each for MAC, ANC, and PTH-ANC spectra. The first set of peaks were within 2θ = 26.3° and 26.4° while the second set were within 2θ = 33.2° and 33.3°. This means that the crystalline quality of MAC and ANC is maintained throughout the process of PTH-ANC production.

This study presents cumulative PTH 1–34 released from 2.5 mg PTH-ANC (containing 9.8 µg of PTH 1–34) over a week (168 h) period at pH 7.5. Recent decades have witnessed speedy advancement in the area of drug delivery, with emphasis on sustained release systems, the main purpose of which is to maintain a given concentration of drug locally or systemically for a desired duration of time. An initial burst release of 8.37% of the total released drug was released at 0 h followed by a marked decline at 0.5 h and steady rise to attain a highest peak by 24 h. It was then sustained for the remaining period of the release. A similar pattern of PTH 1–34 release was observed by Narayanman et al. and Eswaramoorthy et al. in studies on PTH 1–34-loaded polymers. Drug release patterns have been observed to take two forms: a slow zero (first-order rate) or an initial swift dose that is followed by sustained slow zero release of incorporated drug. It was observed from this present study that relative to the control, cellular viabilities in the PTH 1–34, ANC-, and PTH-ANC-treated cells were inversely proportional to their concentrations during the incubation periods of 24, 48, and 72 h. Generally, ANC and PTH-ANC sustained better proliferations in the 24 and 48 h periods. PTH 1–34 sustained better viability over PTH-ANC at a concentration of 2.5 mg/mL in the 24 h period. ANC-treated wells had best viability of cells during the 24 and 48 h periods, whereas PTH-ANC sustained best viability at the 72 h period. This shows the
dual potential of ANC as a bone anabolic and a nanocarrier for sustained release of PTH 1-34. The cockle shell-derived CaCO₃ nanocrystal is a facilitator of osteoblast proliferation, differentiation, and adhesion.⁴⁸ Tran and Webster⁴⁹ observed an increase in cell viability without apparent toxicity from a similar research on pearl shell nanograde powder. Hydroxyapatite coated magnetic nanoparticles were also observed to cause increased osteoblast proliferation when compared to the uncoated form after 5 days of treatment.⁵⁰

Conclusion
Conclusively, although earlier researchers do not consider the capability of CaCO₃ as a nanocarrier for osteoporosis outcomes, the present study attests to the fact that ANC, just like other CaCO₃ nanoparticles derived from shells, is a potential bone anabolic that can synergize with encapsulated antiosteoporotic agent for a cost-effective, safe, and better management of osteoporosis due to its biogenic nature.

Disclosure
The authors report no conflicts of interest in this work.

References
8. Lily E. Medication guide Forteo teriparatide rDNA origin injection; 2008;5:505.
Supplementary materials

Figure S1 PTH 1-34 calibration curve.
Abbreviation: PTH 1-34, parathyroid hormone 1-34.

Table S1 Cumulative PTH 1-34 release from PTH-ANC at pH 7.5 over 168 h

<table>
<thead>
<tr>
<th>Time (hour)</th>
<th>Quantity released (ng)</th>
<th>Percent released (%)</th>
<th>Cumulative percentage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>820.69</td>
<td>8.37</td>
<td>8.37</td>
</tr>
<tr>
<td>0.5</td>
<td>195.00</td>
<td>1.99</td>
<td>10.36</td>
</tr>
<tr>
<td>1</td>
<td>538.46</td>
<td>5.50</td>
<td>15.86</td>
</tr>
<tr>
<td>3</td>
<td>833.82</td>
<td>8.51</td>
<td>24.37</td>
</tr>
<tr>
<td>9</td>
<td>809.38</td>
<td>8.26</td>
<td>32.63</td>
</tr>
<tr>
<td>24</td>
<td>911.95</td>
<td>9.31</td>
<td>41.93</td>
</tr>
<tr>
<td>48</td>
<td>779.61</td>
<td>7.96</td>
<td>49.89</td>
</tr>
<tr>
<td>72</td>
<td>448.89</td>
<td>4.58</td>
<td>54.47</td>
</tr>
<tr>
<td>96</td>
<td>417.43</td>
<td>4.26</td>
<td>58.73</td>
</tr>
<tr>
<td>120</td>
<td>398.45</td>
<td>4.07</td>
<td>62.79</td>
</tr>
<tr>
<td>144</td>
<td>168.74</td>
<td>1.72</td>
<td>64.52</td>
</tr>
<tr>
<td>168</td>
<td>485.94</td>
<td>4.96</td>
<td>69.47</td>
</tr>
</tbody>
</table>

Abbreviations: PTH 1-34, parathyroid hormone 1-34; PTH-ANC, PTH 1-34-loaded cockle shell aragonite calcium carbonate nanocrystals.

\[ y = -0.177 \ln(x) + 0.9111 \]
\[ R^2 = 0.9707 \]